A Cell Cycle Regulator Potentially Involved in Genesis of Many Tumor Types
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
A putative tumor suppressor locus on the short arm of human chromosome 9 has been localized to a region of less than 40 kilobases by means of homozygous deletions in melanoma cell lines. This region contained a gene, Multiple Tumor Suppressor 1 (MTS1), that encodes a previously identified inhibitor (p16) of cyclin-dependent kinase 4. MTS1 was homozygously deleted at high frequency in cell lines derived from tumors of lung, breast, brain, bone, skin, bladder, kidney, ovary, and lymphocyte. Melanoma cell lines that carried at least one copy of MTS1 frequently carried nonsense, missense, or frameshift mutations in the gene. These findings suggest that MTS1 mutations are involved in tumor formation in a wide range of tissues.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Within months of its discovery, the INK4a (CDKN2A) and the genetically linked INK4b gene (CDKN2B) (36) were implicated in a reverse genetic screen to play tumor suppressive roles in familial melanoma (37).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [37]
Citations
Cites
Molecular Cloning: A Laboratory Manual
Sambrook, J., Fritsch, E., & Maniatis, T. (1989) · UCLA - Biblioteca de Ciencias de la Salud · Cited by 133,589
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
A novel cyclin encoded by a bcl1-linked candidate oncogene
Motokura, T., Bloom, T., Kim, H. G., Jüppner., H., Ruderman, J. V., Kronenberg, H. M., & Arnold, A. (1991) · Nature · doi:10.1038/350512a0 · Cited by 1,265
Functional interactions of the retinoblastoma protein with mammalian D-type cyclins
Ewen, M. E., Sluss, H. K., Sherr, C. J., Matsushime, H., Kato, J.-Y., & Livingston, D. M. (1993) · Cell · doi:10.1016/0092-8674(93)90136-e · Cited by 1,010
Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit
Gu, Y., Turck, C. W., & Morgan, D. O. (1993) · Nature · doi:10.1038/366707a0 · Cited by 764
p53: At the Crossroads of Molecular Carcinogenesis and Risk Sssessment
Harris, C. C. (1993) · Science · doi:10.1126/science.8266092 · Cited by 475
PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma.
Rosenberg, C. L., Wong, E., Petty, E. M., Bale, A. E., Tsujimoto, Y., Harris, N. L., & Arnold, A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.21.9638 · Cited by 432
Research works printed but not linked: 1
- Weaver-Feldhaus, J., Proceedings of the National Academy of Sciences of the United States of America 91: 7563 (1994).
Cited by
Items 901–1,000 of 1,005
Delineation of two distinct deleted regions on chromosome 9 in human non‐melanoma skin cancers
Quinn, A., Sikkink, S. K., & Rees, J. L. (1994) · Genes Chromosomes and Cancer · doi:10.1002/gcc.2870110404 · Cited by 62
Biochemical Characterization of p16 - and p18-containing Complexes in Human Cell Lines
Ragione, F. D., Russo, G. L., Oliva, A., Mercurio, C., Mastropietro, S., Pietra, V. D., & Zappia, V. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.27.15942 · Cited by 56
p15ink4B and p16ink4 gene inactivation in acute lymphocytic leukemia
Rasool, O., Heyman, M., Brandter, L., Liu, Y., Grander, D., Soderhall, S., & Einhorn, S. (1995) · Blood · doi:10.1182/blood.v85.12.3431.bloodjournal85123431 · Cited by 56
Andreasson, P., Johansson, B., Arheden, K., Billström, R., Mitelman, F., & Höglund, M. (1997) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199706)19:2<77::aid-gcc2>3.0.co;2-x · Cited by 42
A novel immunocompetent murine model for Candida albicans-promoted oral epithelial dysplasia
Dwivedi, P. P., Mallya, S., & Dongari-Bagtzoglou, A. (2009) · Medical Mycology · doi:10.1080/13693780802165797 · Cited by 55
“Protein p16, is the product of the cyclin dependent kinase inhibitor 2A (CDKN2A) gene located at chromosome 9p21 [63,64] and plays a crucial role in the negative regulation of the cell cycle [42,64-66].”
BackgroundMethyl-CpG binding proteins and cancer: are MeCpGs more important than MBDs?
Prokhortchouk, E., & Hendrich, B. (2002) · Oncogene · doi:10.1038/sj.onc.1205631 · Cited by 65
“These authors chose to investigate whether MBD2 and MeCP2 bind to the promoters of two important cell cycle regulatory genes, p14/ARF and p16/INK4A (Kamb et al., 1994).”
BackgroundHe, H., Zhuo, R., Dai, J., Wang, X., Huang, X., Wang, H., & Xu, D. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14295 · Cited by 56
Lan, J. Q., Xiong, Y.-Y., Lin, Y.-X., Wang, B.-C., Gong, L.-L., Hui-sen, X., & 郭广松 (2003) · World Journal of Gastroenterology · doi:10.3748/wjg.v9.i1.54 · Cited by 57
Sulaimon, S. S., & Kitchell, B. E. (2003) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2003.tb02513.x · Cited by 65
Rb/E2F: A two-edged sword in the melanocytic system
Halaban, R. (2005) · Cancer and Metastasis Reviews · doi:10.1007/s10555-005-1582-z · Cited by 61
Malumbres, M., de Castro, I. P., Santos, J., Piqueras, J. F., & Pellicer, À. (1999) · Oncogene · doi:10.1038/sj.onc.1202299 · Cited by 64
“The p16INK4a and p15INK4b genes, which lie very close in the human and murine chromosomes (Kamb et al., 1994; Quelle et al., 1995), are frequently deleted in a wide range of tumors (Harper and Elledge, 1996; Hirama and Koe er, 1995).”
BackgroundExpression of p16INK4A and p14ARF in hematological malignancies
Taniguchi, T., Chikatsu, N., Takahashi, S., Fujita, A., Uchimaru, K., Asano, S., Fujita, T., & Motokura, T. (1999) · Leukemia · doi:10.1038/sj.leu.2401557 · Cited by 57
The therapeutic potential of targeting the cell cycle
Webster, K. R. (1998) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.7.6.865 · Cited by 60
Jagasia, A. A., Block, J. A., Qureshi, A., Díaz, M. O., Nobori, T., Gitelis, S., & Iyer, A. P. (1996) · Cancer Letters · doi:10.1016/0304-3835(96)04274-7 · Cited by 56
Serra, A., Gottardi, E. M., Ragione, F. D., Saglio, G. N., & Iolascon, A. (1995) · British Journal of Haematology · doi:10.1111/j.1365-2141.1995.tb05358.x · Cited by 62
Genetic studies and molecular markers of bladder cancer
Cordon‐Cardo, C., Sheinfeld, J., & Dalbagni, G. M. (1997) · Seminars in Surgical Oncology · doi:10.1002/(sici)1098-2388(199709/10)13:5<342::aid-ssu8>3.0.co;2-d · Cited by 55
Reddy, K. B., Krueger, J. S., B. Kondapaka, S., & Diglio, C. A. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990719)82:2<268::aid-ijc18>3.0.co;2-4 · Cited by 149
Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Mesothelioma
Sandberg, A. A., & Bridge, J. A. (2001) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(01)00432-0 · Cited by 58
Inhibitors of cyclin-dependent kinase and cancer
Biggs, J. R., & Kraft, A. S. (1995) · Journal of Molecular Medicine · doi:10.1007/bf00198902 · Cited by 60
“jority of tumor cell lines examined [9, 10]; however, p16”
Mutations of theINK4aLocus in Squamous Cell Carcinomas of Human Skin
Kubo, Y., Urano, Y., Matsumoto, K., Ahsan, K., & Arase, S. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6217 · Cited by 61
Wolf, G., Wenzel, U. O., Ziyadeh, F. N., & Stahl, R. A. K. (1999) · Diabetologia · doi:10.1007/s001250051314 · Cited by 57
“the INK4 family contain four or more ankyrin repeats and p16INK4 is a tumour suppressor gene [37, 38].”
BackgroundHypermethylation of the CDKN2/p16INK4A Promotor in Thyroid Carcinogenesis
Boltze, C., Zack, S., Quednow, C., Bettge, S., Roessner, A., & Schneider‐Stock, R. (2003) · Pathology - Research and Practice · doi:10.1078/0344-0338-00436 · Cited by 54
Frequent Inactivation of a Putative Tumor Suppressor, Angiopoietin-Like Protein 2, in Ovarian Cancer
Kikuchi, R., Tsuda, H., Kozaki, K., Kanai, Y., Kasamatsu, T., Sengoku, K., Hirohashi, S., Inazawa, J., & Imoto, I. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0062 · Cited by 54
Genetics of Diabetes Complications
Doria, A. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0147-x · Cited by 61
Simon, M., Park, T., Köster, G., Mahlberg, R., Hackenbroch, M., Boström, J. P., Löning, T., & Schramm, J. (2001) · Journal of Neuro-Oncology · doi:10.1023/a:1013863630293 · Cited by 57
Mutations of the Ki-ras, p53 andAPC genes in adenocarcinomas of the human small intestine
Arai, M., Shimizu, S., Imai, Y., Nakatsuru, Y., Oda, H., Oohara, T., & Ishikawa, T. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970207)70:4<461::aid-ijc14>3.0.co;2-i · Cited by 79
Factors That Affect Skin Aging: A Cohort-Based Survey on Twins
Martires, K. J., Fu, P., Polster, A. M., Cooper, K. D., & Baron, E. D. (2009) · Archives of Dermatology · doi:10.1001/archdermatol.2009.303 · Cited by 54
Familial aggregation of melanoma risks in a large population-based sample of melanoma cases
Begg, C. B., Hummer, A., Mujumdar, U., Armstrong, B. K., Kricker, A., Marrett, L. D., Millikan, R. C., Gruber, S. B., Anton‐Culver, H., Klotz, J. B., et al. (2004) · Cancer Causes & Control · doi:10.1007/s10522-004-2474-2 · Cited by 54
GRUBER, S. B., & ARMSTRONG, B. K. (2006) · Cancer Epidemiology and Prevention · doi:10.1093/acprof:oso/9780195149616.003.0063 · Cited by 52
CDK-independent activities of D type cyclins
Bernards, R. (1999) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(99)00024-4 · Cited by 70
Cell cycle control of DNA replication
Fotedar, R., & Fotedar, A. (1995) · Springer eBooks · doi:10.1007/978-1-4615-1809-9_6 · Cited by 59
The national cancer data base report on gastric carcinoma
Hundahl, S. A., Menck, H. R., Mansour, E. G., & Winchester, D. P. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971215)80:12<2333::aid-cncr15>3.0.co;2-v · Cited by 135
Robertson, G. P., Herbst, R. A., Nagane, M., Huang, H.-J. S., & Cavenee, W. K. (1999) · PubMed · Cited by 56
Weber, B. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00026-0 · Cited by 81
Pal, A., Potjer, T. P., Thomsen, S. K., Ng, H. J., Barrett, A., Scharfmann, R., James, T. J., Bishop, D. T., Karpe, F., Godsland, I. F., et al. (2015) · Diabetes · doi:10.2337/db15-0602 · Cited by 65
Molecular Aspects of Melanocytic Dysplastic Nevi
Hussein, M. R., & Wood, G. S. (2002) · Journal of Molecular Diagnostics · doi:10.1016/s1525-1578(10)60684-8 · Cited by 61
Malignant melanoma and lymphoproliferative malignancy: is there a shared aetiology?
McKenna, D. B., Doherty, V. R., McLaren, K. M., & Hunter, J. A. (2000) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2000.03610.x · Cited by 53
Alterations of p16 and Prognosis in Biliary Tract Cancers from a Population-Based Study in China
Ueki, T., Hsing, A. W., Gao, Y.-T., Wang, B.-S., Shen, M.-C., Cheng, J., Deng, J., Fraumeni, J. F., & Rashid, A. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1137-3 · Cited by 62
Becker, T. M., Rizos, H., Kefford, R. F., & Mann, G. J. (2001) · PubMed · Cited by 54
Comparative structure and characterization of a CDKN2 gene in a Xiphophorus fish melanoma model
Kazianis, S., Morizot, D. C., Coletta, L. D., Johnston, D., Woolcock, B. W., Vielkind, J., & Nairn, R. (1999) · Oncogene · doi:10.1038/sj.onc.1202884 · Cited by 57
“…groups that had localized tumor suppressor e ects to human chromosomal region 9p21; this region had been known to undergo chromosomal translocations, inversions, and heterozygous and homozygous deletions in cell lines derived from many di erent tumor types (Kamb et al., 1994; Nobori et al., 1994).”
BackgroundMusgrove, E. A., Hui, R., Sweeney, K. J. E., Watts, C. K. W., & Sutherland, R. L. (1996) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/bf02013639 · Cited by 55
Gonzalez‐Quevedo, R., Iniesta, P., Morán, A., de Juan, C., Sánchez-Pernaute, A., Fernández, C., Torres, A., Díaz-Rubio, E., Balibrea, J.-L., & Benito, M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.254 · Cited by 55
Mihic‐Probst, D., Saremaslani, P., Komminoth, P., & Heitz, P. U. (2003) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-003-0897-9 · Cited by 56
Nicholson, S. A., Okby, N. T., Ma, K., Welsh, J. A., McMenamin, M. G., Travis, W. D., Jett, J. R., Tazelaar, H. D., Trastek, V. F., Pairolero, P. C., et al. (2001) · PubMed · Cited by 63
Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression
Nozaki, M., Tada, M., Kobayashi, H., Zhang, C.-L., Sawamura, Y., Abe, H., Ishii, N., & Meir, E. G. V. (1999) · Neuro-Oncology · doi:10.1215/s1522851798000179 · Cited by 53
Mutational Analysis of CDKN2 (CDK4I/MTS1) Gene in Tissues and Cell Lines of Human Prostate Cancer
Komiya, A., Suzuki, H., Aida, S., Yatani, R., & Shimazaki, J. (1995) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1995.tb02443.x · Cited by 53
Screening for CDKN2A Mutations in Hereditary Melanoma
Goldstein, A. M., & Tucker, M. A. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.10.676 · Cited by 57
Dichotomy of astrocytoma migration and proliferation
Giese, A., Loo, M. A., Tran, N., Haskett, D., Coons, S. W., & Berens, M. E. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960717)67:2<275::aid-ijc20>3.0.co;2-9 · Cited by 399
Similar outcome of elderly patients in Intergroup Trial 0096
Yuen, A. R., Zou, G., Turrisi, A. T., Sause, W. T., Komaki, R. R., Wagner, H., Aisner, S. C., Livingston, R. B., Blum, R. H., & Johnson, D. H. (2000) · Cancer · doi:10.1002/1097-0142(20001101)89:9<2006::aid-cncr18>3.0.co;2-7 · Cited by 140
Hereditary Tumor Syndromes and Gliomas
Reuß, D., & von Deimling, A. (2009) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-540-31206-2_5 · Cited by 60
Citation classics: Top 50 cited articles in ‘respiratory system’
Tam, W., Wong, E. L., Wong, F. C. Y., & Hui, D. S. C. (2012) · Respirology · doi:10.1111/j.1440-1843.2012.02262.x · Cited by 53
p16INK4A Positively Regulates Cyclin D1 and E2F1 through Negative Control of AUF1
Al‐Khalaf, H. H., Çolak, D., Al‐Saif, M., AlBakheet, A., Hendrayani, S., Al‐Yousef, N., Kaya, N., Khabar, K. S. A., & Aboussekhra, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021111 · Cited by 57
Conway, C., Beswick, S., Elliott, F., Chang, Y., Randerson‐Moor, J. A., Harland, M., Affleck, P., Marsden, J., Sanders, D. S., Boon, A., et al. (2010) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20753 · Cited by 56
“CDKN2A was identified first as a tumor suppressor gene commonly deleted/mutated in tumor cell lines (Kamb et al., 1994a) and subsequently its role as a high-risk susceptibility gene in melanoma families was elucidated (Kamb et al., 1994b).”
BackgroundL??pez-Guerrero, J. A., L??pez-Gin??s, C., Pell??n, A., Cardá, C., & Llombart‐Bosch, A. (2004) · Diagnostic Molecular Pathology · doi:10.1097/00019606-200406000-00004 · Cited by 52
Tchernev, G., & Orfanos, C. E. (2007) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.2006.00700.x · Cited by 52
Well-differentiated thyroid carcinomas: p53 mutation status and microvessel density
Goldenberg, J. D., Portugal, L. G., Wenig, B. L., Ferrer, K., Wu, J. C., & Sabnani, J. (1998) · Head & Neck · doi:10.1002/(sici)1097-0347(199803)20:2<185::aid-hed17>3.0.co;2-l · Cited by 29
Induction of Cell Activation Processes by Low Frequency Electromagnetic Fields
Simkó, M. (2004) · The Scientific World JOURNAL · doi:10.1100/tsw.2004.174 · Cited by 56
“In particular two of these CKIs, p16 and p21, have been implicated as potential tumor-suppressor genes in cancer[87,88].”
BackgroundHigh- and low-penetrance cutaneous melanoma susceptibility genes
Fargnoli, M. C., Argenziano, G., Zalaudek, I., & Peris, K. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.5.657 · Cited by 62
“113 van Haeringen A, Bergman W, Nelen MR et al. Exclusion of the dysplastic nevus syndrome (DNS) locus from the short arm of chromosome 1 by linkage studies in Dutch families.”
BackgroundElevated activity of cyclin-dependent kinase 6 in human squamous cell carcinoma lines.
Timmermann, S., Hinds, P. W., & Münger, K. (1997) · PubMed · Cited by 61
Tahara, H., Smith, A. P., Gaz, R. D., & Arnold, A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.10.3663 · Cited by 54
Owen, J. D., Strieter, R., Burdick, M., Haghnegahdar, H., Nanney, L., Shattuck-Brandt, R., & Richmond, A. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970926)73:1<94::aid-ijc15>3.0.co;2-5 · Cited by 133
Somatic genetic alterations in human malignant mesothelioma (review).
Lee, W. C., & Testa, J. R. (1999) · International Journal of Oncology · doi:10.3892/ijo.14.1.181 · Cited by 52
p16INK4a Is Selectively Silenced in the Tumoral Progression of Mycosis Fungoides
Navas, I. C., Algara, P., Mateo, M. S., Martínez, P., García, C., Rodriguez, J. L., Vanaclocha, F., Barrientos, N., Iglesias, L., Sánchez, L., et al. (2002) · Laboratory Investigation · doi:10.1038/labinvest.3780405 · Cited by 55
“Genetic and epigenetic alterations of the INK4/ARF locus on 9p21 are one of the most frequent molecular alterations observed in human tumorigenesis (Cairns et al, 1995; Kamb et al, 1994).”
BackgroundInhibiting tumorigenic potential by restoration of p16 in nasopharyngeal carcinoma
Wang, G. L., Lo, K. W., Tsang, K. S., Chung, N. Y. F., Tsang, Y. S., Cheung, S., Lee, J. C. K., & Huang, D. P. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690818 · Cited by 53
“Recent studies have localized three INK4 family genes, p16 (CNKN2A, MTS1, INK4A), p15 (CNKN2B, INK4B) and p19 (ARF) to this affected region (Kamb et al 1994; Hannon Beach, 1994; Nobori et al 1994; Chan et al, 1995).”
BackgroundGonzález, M. V., Pello, M. F., López‐Larrea, C., Suarez, C. M., Menéndez, M., & Coto, E. (1997) · Journal of Clinical Pathology · doi:10.1136/jcp.50.6.509 · Cited by 55
CDKN2/p16 Predicts Survival in Oligodendrogliomas: Comparison with Astrocytomas
Miettinen, H., Kononen, J., Sallinen, P. K., Alho, H., Helén, P., Helin, H., Kalimo, H., Paljärvi, L., Isola, J., & Haapasalo, H. (1999) · Journal of Neuro-Oncology · doi:10.1023/a:1006185220369 · Cited by 56
Adachi, Y., Lakka, S. S., Chandrasekar, N., Yanamandra, N., Gondi, C. S., Mohanam, S., Dinh, D. H., Olivero, W. C., Gujrati, M., Tamiya, T., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104334200 · Cited by 56
RetractedAlterations of CDKN2 (p16) in non‐small cell lung cancer
de Vos, S., Miller, C. W., Takeuchi, S., Gombart, A. F., Cho, S. K., & Koeffler, H. P. (1995) · Genes Chromosomes and Cancer · doi:10.1002/gcc.2870140303 · Cited by 57
An update on the implications of cyclin D1 in melanomas
González‐Ruiz, L., González‐Moles, M. Á., González‐Ruiz, I., Ruiz‐Ávila, I., Ayén, Á., & Ramos‐García, P. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12874 · Cited by 49
Carbonara, C., Longa, L., Grosso, E., Mazzucco, G., Borrone, C., Garrè, M. L., Brisigotti, M., Filippi, G., Scabar, A., Giannotti, A., et al. (1996) · Genes, Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199601)15:1<18::aid-gcc3>3.0.co;2-7 · Cited by 131
Chironna, M., Calabrò, M. L., Quarto, M., Germinario, C. A., Fiore, J. R., Favero, A., Potenza, D., Chieco‐Bianchi, L., & Barbuti, S. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960315)65:6<778::aid-ijc12>3.0.co;2-0 · Cited by 7
Suzuki, E., Imoto, I., Pimkhaokham, A., Nakagawa, T., Kamata, N., Kozaki, K., Amagasa, T., & Inazawa, J. (2007) · Oncogene · doi:10.1038/sj.onc.1210589 · Cited by 51
“…several TSGs, such as SMAD4, RB1, PTEN and p16INK4A, were originally identified from homozygous deletions in cancer cells (Friend et al., 1986; Kamb et al., 1994; Hahn et al., 1996; Li et al., 1997), genetic and epigenetic mechanisms other than homozygous loss could contribute to the loss of…”
BackgroundCho, Y. S., Angove, H. C., Brain, C. T., Chen, C. H.-T., Cheng, H., Cheng, R., Chopra, R., Chung, K., Congreve, M., Dagostin, C., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200241a · Cited by 53
Goldberg, E. K., Glendening, J. M., Karanjawala, Z. E., Sridhar, A., Walker, G. J., Hayward, N. K., Rice, A. J., Kurera, D., Tebha, Y., & Fountain, J. W. (2000) · The American Journal of Human Genetics · doi:10.1086/302999 · Cited by 51
One INK4 gene and no ARF at the Fugu equivalent of the human INK4A/ARF/INK4B tumour suppressor locus
Gilley, J., & Fried, M. (2001) · Oncogene · doi:10.1038/sj.onc.1204933 · Cited by 56
“The closely related INK4A and INK4B genes are two of four known members of the INK4 family of cyclindependent kinase (CDK) inhibitor genes and their degree of relatedness suggests that they arose as the result of a tandem duplication (Ruas and Peters 1998; Kamb et al., 1994).”
BackgroundDifferential retinoblastoma and p16INK4A protein expression in neuroendocrine tumors of the lung
Dosaka‐Akita, H., Cagle, P. T., Hiroumi, H., Fujita, M., Yamashita, M., Sharma, A., Kawakami, Y., & Benedict, W. F. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000201)88:3<550::aid-cncr9>3.0.co;2-d · Cited by 53
Telomerase as a tool for the differential diagnosis of human hepatocellular carcinoma
Nouso, K., Urabe, Y., Higashi, T., Nakatsukasa, H., Hino, N., Ashida, K., Kinugasa, N., Yoshida, K., Uematsu, S., & Tsuji, T. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960715)78:2<232::aid-cncr7>3.0.co;2-n · Cited by 84
Baumgartner, R., Fernandez-Catalan, C., Winoto, A., Huber, R., Engh, R. A., & Holak, T. A. (1998) · Structure · doi:10.1016/s0969-2126(98)00128-2 · Cited by 64
Coleman, W. B., & Tsongalis, G. J. (1995) · Clinical Chemistry · doi:10.1093/clinchem/41.5.644 · Cited by 64
Goodman, G. E. (2000) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(99)00074-8 · Cited by 54
Non‐Hodgkin's lymphoma and skin malignancies‐shared etiology?
Hall, P. N., Rosendahl, I. K., Mattsson, A., & Einhorn, S. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910620505 · Cited by 52
Molecular Mechanisms of Myelodysplastic Syndrome
Hirai, H. (2003) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyg037 · Cited by 62
“The cyclin-dependent kinase inhibitor (CDKI) genes p15INK4B and p16INK4A are frequently inactivated by genetic alterations in many malignant tumors and have been shown to be tumor-suppressor genes (67,68).”
BackgroundGenetic and Biochemical Alterations in Non-Small Cell Lung Cancer
Johnson, J. L., Pillai, S., & Chellappan, S. (2012) · Biochemistry Research International · doi:10.1155/2012/940405 · Cited by 59
“[238] A.”
Unmasking the Lung Cancer Epigenome
Belinsky, S. A. (2015) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021014-072018 · Cited by 54
Wong, M. P., Cheung, N., Yuen, S. T., Leung, S. Y., & Chung, L. P. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990611)81:6<851::aid-ijc2>3.0.co;2-d · Cited by 125
Filippova, G. N., Lindblom, A., Meincke, L. J., Klenova, E. M., Neiman, P. E., Collins, S. J., Doggett, N. A., & Lobanenkov, V. V. (1998) · Genes, Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199805)22:1<26::aid-gcc4>3.0.co;2-9 · Cited by 148
Cyclin-Dependent Kinase Inhibitors and Human Cancer
Kamb, A. (1998) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-71941-7_7 · Cited by 57
Chen, Q., Luo, G., Li, B., & Samaranayake, L. P. (1999) · Journal of Oral Pathology and Medicine · doi:10.1111/j.1600-0714.1999.tb02016.x · Cited by 56
DNA aberrations in urinary bladder cancer detected by flow cytometry and FISH
Sauter, G., Gasser, T. C., Moch, H., Richter, J., Jiang, F., Albrecht, R., Novotny, H., Wagner, U. A., Bubendorf, L., & Mihatsch, M. J. (1997) · Urological Research · doi:10.1007/bf00942046 · Cited by 50
“Chromosome 9 carries one or several tumor suppressor genes with relevance for bladder cancer, loss of chromosome Y has been suggested to have prognostic significance in bladder tumors, and for chromosome 7 it was suggested that a trisomy could represent an initial event in bladder carcinogenesis [11, 16, 17].”
BackgroundThe Growth-Regulatory Role of p21 (WAF1/CIP1)
Gartel, A. L., & Tyner, A. L. (1998) · Progress in molecular and subcellular biology · doi:10.1007/978-3-642-72149-6_4 · Cited by 57
Matsuda, H., Konishi, N., Hiasa, Y., Hayashi, I., Tsuzuki, T., Tao, M., Kitahori, Y., Yoshioka, N., Kirita, T., & Sugimura, M. (1996) · Journal of Oral Pathology and Medicine · doi:10.1111/j.1600-0714.1996.tb01377.x · Cited by 63
Hansson, J. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-6448-9_13 · Cited by 61
Technological advances for the detection of melanoma
Fried, L., Tan, A., Bajaj, S., Liebman, T. N., Polsky, D., & Stein, J. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.03.121 · Cited by 54
Familial melanoma: a complex disorder leading to controversy on DNA testing
de Snoo, F. A., Bergman, W., & Gruis, N. A. (2003) · Familial Cancer · doi:10.1023/a:1025758527675 · Cited by 49
“A second locus for a tumour suppressor gene leading to melanoma susceptibility was indicated by cytogenetic and LOH studies on chromosome 9p. Lod scores over 10 were obtained by linkage analysis in this region [32] which was confirmed by several groups [33‐36] and led to the cloning and identification of the first mel…”
Spieker, N., Beitsma, M. M., Sluis, P. V., Roobeek, I., den Dunnen, J. T., Speleman, F., Caron, H. N., & Versteeg, R. (2000) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(200002)27:2<169::aid-gcc8>3.0.co;2-m · Cited by 18
Interphase Cytogenetic Analysis of Solid Tumors by Non-Isotopic DNA in situ Hybridization
Alers, J. C., & van Dekken, H. (1996) · Progress in Histochemistry and Cytochemistry · doi:10.1016/s0079-6336(96)80017-9 · Cited by 50
Correlation between p14ARF/p16INK4A expression and HPV infection in uterine cervical cancer
Kanao, H., Enomoto, T., Ueda, Y., Fujita, M., Nakashima, R., Ueno, Y., Miyatake, T., Yoshizaki, T., Buzard, G. S., Kimura, T., et al. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.03.030 · Cited by 52
Chen, Z., Olopade, O. I., & Savarese, T. M. (1997) · Molecular Pharmacology · doi:10.1124/mol.52.5.903 · Cited by 49
Cooperativity of p19ARF, Mdm2, and p53 in murine tumorigenesis
Moore, L., Venkatachalam, S., Vogel, H., Watt, J. C., Wu, C.-L., Steinman, H., Jones, S. N., & Donehower, L. A. (2003) · Oncogene · doi:10.1038/sj.onc.1206985 · Cited by 48
“Deletions or silencing of the INK4a/ARF locus are frequently observed in human tumors (Kamb et al., 1994).”
BackgroundThe Retinoblastoma Gene Family in Cell Cycle Regulation and Suppression of Tumorigenesis
Dannenberg, J.-H., & te Riele, H. P. J. (2006) · Results and Problems in Cell Differentiation · doi:10.1007/400_002 · Cited by 47
Metadata
- Authors
- Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H.
- Affiliations
- Myriad Genetics (US)
- Memorial Sloan Kettering Cancer Center (US)
- Cross Cancer Institute (CA)
- National Institutes of Health (US)
- University of Utah (US)
- Venue
- Science
- Published
- 1994-04-15
- Volume
- 264
- Issue
- 5157
- Pages
- 436-440
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1983348452
- Cited by
- 2,751
- References
- 26
- Citations by year
- 2026: 11 · 2025: 8 · 2024: 18 · 2023: 12 · 2022: 22 · 2021: 31 · 2020: 24 · 2019: 23 · 2018: 34 · 2017: 45 · 2016: 20 · 2015: 32 · 2014: 31 · 2013: 44 · 2012: 54
- FWCI
- 115.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p01ca048711-05)
- National Cancer Institute (CA 48711)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- CDKN2A, p16, tumor suppressor, chromosome 9p, homozygous deletion, melanoma cell lines, CDK4, cell cycle regulation, genetic mutations
- MeSH terms
- Base Sequence, Carrier Proteins, Cell Cycle, Chromosomes, Human, Pair 9, Cosmids, Exons, Humans, Introns, Melanoma, Molecular Sequence Data, Mutation, Neoplasms, Proto-Oncogene Proteins, Tumor Cells, Cultured, Genes, Tumor Suppressor, Gene Deletion, Cyclin-Dependent Kinases, Cyclin-Dependent Kinase Inhibitor p16, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.